Yisheng Completes Successful Phase I Test of Hepatitis B Vaccine

Yisheng Biopharma of Beijing completed a Phase I trial of its novel PIKA hepatitis B vaccine, which both treats and prevents the disease. The vaccine includes Yisheng's double-stranded RNA analog (PIKA) adjuvant that acts as a toll-like receptor 3 agonist. In 32 healthy volunteers, the vaccine was well tolerated and created immunogenicity in the subjects. Previously, the PIKA technology has been validated in several rabies vaccine trials, and earlier this month, Yisheng announced it would add the technology to an Scripps Research Institute AIDS vaccine for clinical testing. More details.... Share this with colleagues: // //